Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Both award types require continued employment on the applicable vesting dates.

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) granted equity awards to two newly hired employees on November 1, 2026, as employment inducements.

The awards include options to purchase 24,650 shares and restricted stock units representing the right to receive 5,300 shares. The options have a ten-year term and a $19.68 exercise price, equal to the stock’s closing price on the grant date. Both award types vest over four years. The Compensation Committee approved the grants under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.24,650 stock options at a $19.68 exercise price create potential dilution as employment awards.
• Minor point. Forward-looking: it has not happened yet and may not happen.5,300 shares underlying restricted stock units create potential dilution as employment awards.

Key Figures

Options granted: 24,650 shares RSUs granted: 5,300 shares Employees receiving awards: 2 employees +4 more

Options granted

24,650 shares

Inducement awards to newly hired employees

RSUs granted

5,300 shares

Inducement awards to newly hired employees

Employees receiving awards

2 employees

New hires

Option exercise price

$19.68 per share

Equal to the common-stock closing price on the grant date

Option term

10 years

Stock options

Award vesting period

4 years

Options and RSUs, subject to continued employment

Initial vesting

25% after 12 months

Options and RSUs

Historical Context

1 past event · Latest: Oct 05

1 event

1. Oct 05

   Inducement grant

   24h Move

   -1.4%

   Prior inducement award covered options and RSUs for nine new employees under the same plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"restricted stock units (“RSUs”) representing the right to receive"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 24,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 5,300 shares of Vor Bio’s common stock to 2 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). 

The stock options have a ten-year term, and an exercise price of $19.68 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Vor Bio grant to its new employees?

Vor Bio granted two newly hired employees options to purchase 24,650 shares and restricted stock units covering 5,300 shares on November 1, 2026. The options have a ten-year term and an exercise price of $19.68 per share.

How do Vor Bio’s November 2026 inducement awards vest?

Both award types vest over four years, with 25% vesting after 12 months. The remaining option shares vest monthly over the following 36 months, while the remaining restricted stock units vest quarterly over that period. Vesting requires continued employment on the applicable vesting dates.